Ecallantide
Aliases: Kalbitor
Last verified: 2026-09-23
The short version
A recombinant peptide (60 aa) — plasma-kallikrein inhibitor for acute hereditary angioedema attacks.
Identity & type
- Molecular type
- peptide
- Origin
- A recombinant peptide (60 aa) — plasma-kallikrein inhibitor for acute hereditary angioedema attacks.
Mechanism of action
Inhibits kallikrein → reduced bradykinin production.
Dosing & routes
Official / clinical context
Approved drug — indications, dosing and warnings are defined by the official label. 30 mg SC (3×1 mL).
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
30 mg SC (3×1 mL). Kalbitor: similar to icatibant for HAE attacks; anaphylaxis risk — administered under supervision.
Unverified self-reports. Not medical advice. Not endorsement.
Expected effects (community)
Kalbitor: similar to icatibant for HAE attacks; anaphylaxis risk — administered under supervision.
Protocol — official vs community
Official / label
Kalbitor (acute hereditary angioedema attacks): 30 mg SC as three separate 10 mg injections, administered by a healthcare professional.
Duration: Per-attack. An additional 30 mg may be given within 24 hours if the attack persists.
Unlike icatibant, administration must occur in a healthcare setting because of anaphylaxis risk — this constraint, more than efficacy, explains why patient self-treatment culture formed around icatibant instead.
Community (anecdotal)
Structured protocol data for this entry is coming.
Human evidence
EDEMA trials.
Preclinical evidence
The preclinical phase was completed and submitted to regulators as part of registration; pharmacology and toxicology details are part of the official label.
Known risks
- Anaphylaxis risk (administer in healthcare settings).characterized
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- Real-world data outside controlled trials